Skip to main content
See every side of every news story
Published • loading... • Updated

Ideaya picks cancer drug candidate, targets human trial application in 2027

Summary by Seeking Alpha
Ideaya Biosciences selects IDE101, a preclinical drug candidate for cancers lacking CDKN2A, and aims to seek U.S.

10 Articles

ABC FOX MontanaABC FOX Montana
+7 Reposted by 7 other sources
Center

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of…

·Missoula, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

ABC FOX Montana broke the news in Missoula, United States on Sunday, November 15, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal